

Optimization of the ESC 2023 ACS guidelines after hospital discharge: the Swedish experience

Dr Matthias Lidin

University-nurse R.N, Msci, PhD

Karolinska University Hospital /Karolinska Institute, Stockholm Sweden

02/07/ 2025

Disclosures

Research grants: The Swedish Heart and Lung Foundation


Scientific cooperation: Non

Consultation and lecture fees for the hospital: Astra Zeneca, Amarin, Amgen, NovoNordisk, Sanofi and UCB pharma.

Population: 10.54 million

Overweight BMI over 25 = 52 % (Men 42 % Women 28%)
Obese BMI over 30 = over 20%

Aldersstandardiserade siffror



Year 2024: (SWE) 21400 /patientens
with Myocardial Infarction (MI)



Aim today


The Swedish experience





SWEDHEART


The SWEDHEART Registers
The National Cardiology Quality Registers
Register: 8






Cardiovascular
Round
Table

Secondary prevention according to SEPHIA-rutin

Follow-up 1:year post MI



Results from SWEDEHEART/SEPHIA register







SWEDHEART

Cardiovascular Round Table

To the public



SC

European Society
of Cardiology

SWEDEHEART - Research

Nationwide Cohort Study of Risk of Ischemic Heart Disease in Patients With Celiac Disease

Jonas F. Ludvigsson, MD, PhD; Stefan James, MD, PhD; Johan Askling, MD, PhD; Ulf Stenestrand, MD, PhD†; Erik Ingelsson, MD, PhD

Background—Studies on ischemic heart disease (IHD) incidence in individuals with celiac disease (CD) are and do not take small intestinal pathology into account.

Methods and Results—In this Swedish population-based cohort study, we examined the risk of IHD in patients based on small intestinal histopathology. We defined IHD as death or incident disease in myocardial infarction in Swedish national registers. In 2006 to 2008, we collected duodenal/jejunal biopsy data on villous atrophy; Marsh 3; n=28

(*Circulation*. 2011;123:483-49

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden

Bo Lagerqvist, M.D., Ph.D., Stefan K. James, M.D., Ph.D., Ulf Stenestrand, M.D., Ph.D., Johan Lindbäck, M.Sc., Tage Nilsson, M.D., Ph.D., and Lars Wallentin, M.D., Ph.D., for the SCAAR Study Group*

RRCT

ORIGINAL ARTICLE

Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction

Ole Fröbert, M.D., Ph.D., Bo Lagerqvist, M.D., Ph.D., Göran K. Olivecrona, M.D., Ph.D., Elmir Omerovic, M.D., Ph.D., Thorarinn Gudnason, M.D., Ph.D., Michael Maeng, M.D., Ph.D., Mikael Aasa, M.D., Ph.D., Oskar Angerås, M.D., Fredrik Calais, M.D., Mikael Danielewicz, M.D., David Erlinge, M.D., Ph.D., Lars Hellsten, M.D., et al.

JAMA. 2010;303(12):1167-1172

Influence of Renal Function on Prognosis and outcome determinants after heart failure diagnosis in patients who underwent aortic valvular intervention
Revascularization in Non Myocardial Infarction Silvana Kontogeorgos,¹ Erik Thunström,¹ Aldina Pivodic,^{2,3} Ulf Dahlström,⁴ and Michael Fu¹

Data From the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDHEART)

Karolina Szummer, MD; Pia Lundman, MD, PhD; Stefan H. Jacobson, MD, PhD; Staffan Schön, MD; Johan Lindbäck, MSc; Ulf Stenestrand, MD, PhD; Lars Wallentin, MD, PhD; Tomas Jernberg

(*Circulation*. 2009;120:851

Background—It is unknown whether patients with

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

MAY 7, 2009

VOL. 360 NO. 19

Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden

Stefan K. James, M.D., Ph.D., Ulf Stenestrand, M.D., Ph.D., Johan Lindbäck, M.Sc., Jörg Carlsson, M.D., Ph.D., Fredrik Schersten, M.D., Ph.D., Tage Nilsson, M.D., Ph.D., Lars Wallentin, M.D., Ph.D., and Bo Lagerqvist, M.D., Ph.D., for the SCAAR Study Group*

Circulation

Volume 144, Issue 18, 2 November 2021, Pages 1476-1484
<https://doi.org/10.1161/CIRCULATIONAHA.121.057042>

ORIGINAL RESEARCH ARTICLE

Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Editorial, see p 1485

Ole Fröbert, MD, PhD, Matthias Götzberg, MD, David Erlinge, MD, Zubair Akhtar, MPH, PhD, Evald H. Christiansen, MD, Chandini R. Macintyre, MBBS, PhD, Keith G. Oldroyd,



SWEDHEART

PÅGÅENDE R-RRCT



FULL REVASC



MINOCA -BAT

REDUCE SWEDHEART



Positive factors from the Swedish secondary preventive experience

Cardiovascular
Round
Table




Doctor (Cardiologist)
Medical director




Nurse



Fysio
Training




Audit and Feedback



The public



Leaders – and the Money



Team



- Nurse
- Physician
- Fysioterapeut
- Counsellor

Research/ improvement





The Swedish experience

Tank you

